Generative AI
Elon Musk Says He's Suing OpenAI Because They Abandoned Their Mission. I Think His Real Reason Is Much More Embarrassing.
A new scale of humiliation ritual kicked off this week as Elon Musk's lawsuit against OpenAI went to trial in Silicon Valley. The Tesla CEO, who co-founded OpenAI, is suing the artificial intelligence firm and two of its other co-founders, Sam Altman and Greg Brockman, for diverting from its original nonprofit goal of developing A.I. for the public good in favor of for-profit motives. "This lawsuit is very simple: It is not OK to steal a charity," Musk said on the witness stand on Tuesday. The trial is big by every conceivable measure. Both Musk and OpenAI have mustered high-dollar legal armies who are prepared to wage potentially years of litigation, including this federal trial.
Elon Musk Seemingly Admits xAI Has Used OpenAI's Models to Train Its Own
Elon Musk Seemingly Admits xAI Has Used OpenAI's Models to Train Its Own While answering questions under oath, Musk argued it's standard practice for AI labs to use their competitors' models. While testifying on Thursday in federal court, Elon Musk seemed to indicate that his AI lab may have used OpenAI's models to train xAI's own. He touched upon the topic while sitting on the witness stand answering cross-examination questions from an OpenAI attorney amid his ongoing legal battle against the ChatGPT-maker . Do you know what distillation is? It means to use one AI model to train another AI model.
OpenAI Rolls Out 'Advanced' Security Mode for At-Risk Accounts
OpenAI is rolling out Advanced Account Security for people concerned that their ChatGPT or Codex accounts could be potential targets of phishing attacks. For anyone who fears their ChatGPT and Codex accounts might be targeted by attackers, OpenAI announced on Thursday that it is adding an optional new level of account protection that adds an extra layer of security. Dubbed Advanced Account Security, the feature enforces strict access controls that would make account takeover attacks very difficult. Such measures are not a new idea in the realm of account security. Google, for example, has offered its Advanced Protection account security tier for nearly a decade . But as mainstream AI services rapidly proliferate around the world, there is a pressing need for an array of basic protections to be put in place.
Sam Altman's ChatGPT Couldn't Stop Obsessing Over Goblins
OpenAI desires less regulation, but it still doesn't know how its chatbot works. Get your news from a source that's not owned and controlled by oligarchs. OpenAI admitted it had to develop a specific instruction in the code of its latest model of ChatGPT to stop it from repeatedly referencing "goblins, gremlins, and other creatures." In an explanation posted Wednesday, the company said the "strange habit" came from its chatbot personality feature --specifically for users who chose the "Nerdy" personality. You are an unapologetically nerdy, playful and wise AI mentor to a human.
ChatGPT developed a goblin obsession after OpenAI tried to make it nerdy
Following the release of GPT-5.5 last week, people noticed something funny about OpenAI's latest model. In its Codex coding app, the company left a system prompt instructing GPT 5.5 to avoid mention of goblins, gremlins and other creatures. Yes, you read that right. Never talk about goblins, gremlins, racoons, trolls, ogres, pigeons, or other animals or creatures unless it is absolutely and unambiguously relevant to the user's query, the prompt reads. Apparently, enough people started talking about ChatGPT's creature obsession that OpenAI felt the need to provide an accounting of where the goblins came from .
Google is quietly moving toward ads in Gemini
PCWorld reports that Google is exploring adding advertisements to its Gemini AI app, following OpenAI's implementation of sponsored ads in ChatGPT's free and budget plans. Google's business chief Philipp Schindler views ads as potentially valuable commercial information if properly integrated, while the company has already tested ads in AI Mode and AI Overviews. This move could make AI services more accessible but raises important concerns about maintaining transparency and ensuring ads don't influence AI responses. Putting ads in AI replies is a controversial but lucrative practice, and it's one that OpenAI has already embraced with its free and budget-priced ChatGPT plans. But while Google hasn't gone there yet with Gemini, company execs admitted they're mulling the idea.
ChatGPT has a 'goblin' obsession. Now we know why
PCWorld reports that OpenAI's GPT models, including GPT-5.5, developed an unusual obsession with mentioning goblins and similar creatures in responses. This quirky behavior stemmed from a "Nerdy" personality instruction encouraging playful language use, which became reinforced through AI training processes. The goblin references became so prevalent that OpenAI implemented a direct ban in its Codex app, illustrating the unpredictable nature of large language model training. I've seen some odd AI system instructions in my day, but this one takes the cake: a prompt in OpenAI's Codex command-line app that demands models "never talk about goblins, gremlins, trolls, ogres, pigeons, or other animals or creatures."
Reid Hoffman Thinks Doctors Should Ask AI for a Second Opinion
The LinkedIn cofounder now has an AI drug discovery startup--and thinks not asking chatbots for medical advice is "bordering on committing malpractice." Following a three-decade career at the helm of some of Silicon Valley's most powerful companies--cofounding LinkedIn and sitting on the boards of PayPal and OpenAI-- Reid Hoffman recently turned his attention to health care. Hoffman's startup, Manas AI, is building an AI engine that aims to fast-track the traditionally slow process of drug discovery for various cancers. Inspired by a dinner with renowned cancer physician Siddhartha Mukherjee, the company's cofounder and CEO, its mission statement is to "shift drug discovery from a decade-long process to one that takes a few years." But Hoffman's enthusiasm for generative AI, in particular, stretches far beyond novel drug targets and small molecules.